Gyre Therapeutics' F351 NDA Accepted by China's NMPA for Liver Fibrosis Treatment

summarizeSummary

Gyre Therapeutics announced that China's NMPA has accepted the New Drug Application for its lead drug candidate, F351, for chronic hepatitis B-induced liver fibrosis, marking a significant step towards commercialization in a large market.

check_boxKey Events

• NDA Accepted in China

  China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for F351 (hydronidone), Gyre's lead product candidate.

• Targeting Liver Fibrosis

  F351 is intended for the treatment of chronic hepatitis B-induced liver fibrosis, a condition affecting tens of millions of patients in China.

• Regulatory Progress

  This acceptance follows the NMPA's prior grant of priority review status for F351 in March and the initial NDA submission on March 23, 2026.

• Future U.S. Development

  The company plans to file an Investigational New Drug (IND) application in the U.S. by the end of 2026 for MASH-associated liver fibrosis.

auto_awesomeAnalysis

This 8-K announces a critical regulatory milestone for Gyre Therapeutics, as its New Drug Application (NDA) for F351 (hydronidone) has been accepted for review by China's National Medical Products Administration (NMPA). F351 is the company's lead product candidate for chronic hepatitis B-induced liver fibrosis, a condition affecting a large patient population in China. This acceptance, following a prior priority review designation, de-risks the development pathway and moves the drug closer to potential commercialization, which is vital for the company's future revenue given its recent net losses.